Annovis Bio Inc
NYSE:ANVS
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Annovis Bio Inc
NYSE:ANVS
|
65.5m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
383.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.2B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
181.9B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.9B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.7B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
88.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44.4B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Annovis Bio Inc
Glance View
Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The company is headquartered in Berwyn, Pennsylvania and currently employs 3 full-time employees. The company went IPO on 2020-01-29. The firm is engaged in developing treatments for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s disease in Down syndrome (AD-DS). The firm's lead compound, ANVS401, is an orally administered drug being developed for chronic indications such as AD, PD and AD-DS. The firm's ANVS405 compound is being developed for acute indications, focused on protecting the brain after Traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as ANVS401, but it is given intravenously in cases of acute head and brain trauma. The firm is also developing its compound, ANVS301 to increase cognitive capability in later stages of AD and dementia.
